Spryte Medical has enrolled the first participants in INSYTE, an FDA-approved IDE study evaluating a neuro-specific intravascular optical coherence tomography system during and after endovascular treatment of intracranial aneurysms. The prospective, single-arm, multicenter trial focuses on safety and imaging performance to support diagnostic assessment within the neurovasculature, with additional sites expected to join as enrollment ramps.
The core development is the formal clinical evaluation of a neuro-tailored OCT platform intended to visualize vessel wall morphology and device–tissue interactions in real time, adjunctive to standard angiography. OCT has long been used in coronary interventions to assess stent apposition and neointimal coverage; neuro adoption has lagged due to vessel size, tortuosity, and safety concerns. Bringing a purpose-built catheter and imaging system into a regulated U.S. trial signals FDA’s willingness to test whether high-resolution intraluminal imaging can add actionable insight in aneurysm cases that rely today on DSA, cone-beam CT, and operator judgment.
Strategically, this is an expansion play into an imaging gap that major neurovascular device makers have not fully addressed. If neuro-OCT can reliably depict flow-diverter apposition, branch coverage, and early endothelialization, it could reshape how operators select devices, manage antiplatelet therapy, and decide on retreatment—areas where variability drives costs and inconsistent outcomes. The single-arm design suggests Spryte is first targeting an adjunctive imaging label anchored in technical success, safety, and predefined image-quality thresholds rather than hard clinical endpoints. That pathway aligns with a likely de novo classification given the lack of a neuro predicate, with the option to layer clinical utility claims later if the data show that OCT-guided decisions change outcomes. The move also positions Spryte for partnerships with strategics that control flow diverters, coils, and intrasaccular implants, and with imaging-suite vendors that can integrate OCT data into biplane environments.
For sites, the trial introduces new workflow elements: device handling in distal, tortuous anatomy; blood-clearing protocols to enable OCT acquisition; and additional procedure time, anticoagulation considerations, and staff training. Core lab infrastructure will be critical to standardize image-quality adjudication and catalog management-changing findings, creating opportunities for CROs with device-imaging capabilities and DICOM-integrated data pipelines. Hospital economics will loom large post-approval; neuro-OCT would likely be packaged into inpatient payment, so capital budgeting, disposable pricing, and OR throughput will drive adoption absent dedicated reimbursement.
Sponsors of neurovascular devices should view INSYTE as a test case for elevating imaging-based endpoints in IDEs and post-market studies. If intraprocedural OCT can prospectively document device apposition and vessel healing, it could reduce reliance on surrogate angiographic signs and offer more granular, reproducible evidence for regulators and payers. Conversely, if the learning curve, contrast or flush requirements, and manipulation risk increase complications or prolong cases, enthusiasm will cool quickly.
What to watch next are operational and regulatory signals: image acquisition success rates across diverse anatomies; frequency of OCT-identified issues that alter intraoperative decisions; safety events such as vasospasm, dissection, or thromboembolism relative to standard aneurysm procedures; and six- to twelve-month retreatment or complication rates in the follow-up cohort. Timelines for de novo submission, the breadth of intended-use language FDA will accept for an adjunctive diagnostic tool in the brain, and evidence of industrial partnerships will indicate how quickly this moves from trial to routine use. The broader question is whether high-resolution intravascular imaging becomes a standard layer in neurointerventions—as it did in coronary work—or remains a niche tool reserved for complex anatomy and research protocols.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
1 Comment
Clinical Trial Updates: InSyte Imaging Trial, MDMA PTSD Study & CRISPR T-Cell Therapy
7 months ago[…] details are available in First Participants Enrolled in Spryte Medical’s InSyte […]